DelSiTech Secures EUR 10M Funding to Advance Silica-Based Drug Delivery Platform

New investment from DRW Venture Capital LLC and Tolmar International Ltd Funds will be used to advance its proprietary, silica-based, drug delivery...

January 16, 2024 | Tuesday | News
EU Approves Roche's Tecentriq SC as First Subcutaneous PD-(L)1 Cancer Immunotherapy

Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patien...

January 16, 2024 | Tuesday | News
SyntheticGestalt, Enamine Partner for AI-Driven Drug Discovery Model

SyntheticGestalt, a research and development company specializing in the application of AI to the life sciences domain, and Enamine, the world's leading pr...

January 15, 2024 | Monday | News
Santhera Gets UK Approval for AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy Treatment

Approval by the Medicines and Healthcare products Regulatory Agency (MHRA) of AGAMREE® in the United Kingdom follows marketing authorization for this...

January 12, 2024 | Friday | News
Xeris Biopharma Secures Exclusive Global License for Xeriject® Formulation of Teprotumumab

“We are very excited that our partner is moving forward with licensing the XeriJect technology to further the development of the XeriJect subcutaneou...

January 11, 2024 | Thursday | News
HUTCHMED's Sovleplenib NDA Accepted in China for Immune Thrombocytopenia with Priority Review

— NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 — — NDA is supported b...

January 11, 2024 | Thursday | News
VantAI Renews Partnership with Blueprint Medicines for Innovative Drug Discovery

-- VantAI’s advanced geometric deep learning platform will be used to generate innovative proximity modulating therapeutics, including molecular glue...

January 10, 2024 | Wednesday | News
European Commission Approves Pfizer's TALZENNA® with XTANDI® for Metastatic Prostate Cancer

Pfizer Inc. announced that the European Commission (EC) has approved TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in c...

January 09, 2024 | Tuesday | News
Servier and Base4 Strengthen Collaboration to Propel Progress in Neuroscience Drug Development

Base4 Biotechnology (formerly known as Nymirum) announced that it has expanded its license agreement with Servier to strengthen the companies' strategic co...

January 08, 2024 | Monday | News
BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets

BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditional "hard-to-drug" targets, announced  a strategic collabora...

January 04, 2024 | Thursday | News
Citius Pharma Completes Enrollment in Phase 3 Trial for Mino-Lok® Catheter Salvage

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercial...

January 03, 2024 | Wednesday | News
Junshi Biosciences Gets Approval for Toripalimab as Perioperative Treatment in Resectable NSCLC

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company ded...

January 03, 2024 | Wednesday | News
Pasithea Therapeutics' PAS-004 IND Application Accepted by FDA for Advanced Cancer Patient Evaluation.

-- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 – -- Initial readout expected as ear...

January 03, 2024 | Wednesday | News
Innovent, Xuanzhu Collaborate on Clinical Trial for Advanced Solid Tumors in China

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

December 28, 2023 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close